BUZZ-Polyrizon rises as lab study shows improved nasal delivery for overdose drug

Reuters02-26

** Shares of  drug developer Polyrizon PLRZ.O rise 5.2% to $14.25 premarket

** Co says its experimental naloxone nasal spray delivered about 95% of the drug to the upper nasal cavity — a region that helps rapid absorption — vs ~80% for a commercial product

** PLRZ's naloxone is used to quickly reverse opioid overdoses, per co

** Co says less of the drug remained in the lower nasal area, which could reduce drainage and improve consistency

** Study was conducted at the University of Parma; co says results support its broader intranasal drug delivery strategy

** Shares down over 99% in 2025

(Reporting by Sahil Pandey in Bengaluru)

((Sahil.Pandey@thomsonreuters.com))

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2614421330?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-26 21:28","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2614421330","market":"us","top_or_hot":-1,"title":"BUZZ-Polyrizon rises as lab study shows improved nasal delivery for overdose drug","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BUZZ-Polyrizon rises as lab study shows improved nasal delivery for overdose drug</title></head><body><p>** Shares of  drug developer Polyrizon <span>PLRZ.O</span> rise 5.2% to $14.25 premarket</p><p>** Co says its experimental naloxone nasal spray delivered about 95% of the drug to the upper nasal cavity — a region that helps rapid absorption — vs ~80% for a commercial product</p><p>** PLRZ's naloxone is used to quickly reverse opioid overdoses, per co</p><p>** Co says less of the drug remained in the lower nasal area, which could reduce drainage and improve consistency</p><p>** Study was conducted at the University of Parma; co says results support its broader intranasal drug delivery strategy</p><p>** Shares down over 99% in 2025</p><p> (Reporting by Sahil Pandey in Bengaluru)</p><p> ((Sahil.Pandey@thomsonreuters.com))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BUZZ-Polyrizon rises as lab study shows improved nasal delivery for overdose drug</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBUZZ-Polyrizon rises as lab study shows improved nasal delivery for overdose drug\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-02-26 21:28</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BUZZ-Polyrizon rises as lab study shows improved nasal delivery for overdose drug</title></head><body><p>** Shares of  drug developer Polyrizon <span>PLRZ.O</span> rise 5.2% to $14.25 premarket</p><p>** Co says its experimental naloxone nasal spray delivered about 95% of the drug to the upper nasal cavity — a region that helps rapid absorption — vs ~80% for a commercial product</p><p>** PLRZ's naloxone is used to quickly reverse opioid overdoses, per co</p><p>** Co says less of the drug remained in the lower nasal area, which could reduce drainage and improve consistency</p><p>** Study was conducted at the University of Parma; co says results support its broader intranasal drug delivery strategy</p><p>** Shares down over 99% in 2025</p><p> (Reporting by Sahil Pandey in Bengaluru)</p><p> ((Sahil.Pandey@thomsonreuters.com))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"PLRZ","symbol_name":"Polyrizon Ltd.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260226:nL4N3ZM1AZ:1","article_id":"2614421330","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2614421330","pubTimestamp":1772112500,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BUZZ-Polyrizon rises as lab study shows improved nasal delivery for overdose drug** Shares of drug developer Polyrizon PLRZ.O rise 5.2% to $14.25 premarket** Co says its experimental naloxone nasal spray delivered about 95% of the drug to the upper nasal cavity — a region that helps rapid absorption — vs ~80% for a commercial product** PLRZ's naloxone is used to quickly reverse opioid overdoses, per co** Co says less of the drug remained in the lower nasal area, which could reduce drainage and improve consistency** Study was conducted at the University of Parma; co says results support its broader intranasal drug delivery strategy** Shares down over 99% in 2025  ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"PLRZ":"Polyrizon Ltd."},"translate_title":"BUZZ-Polyrizon上涨，实验室研究显示用药过量药物的鼻腔输送得到改善","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PLRZ":0.9},"content_text":"BUZZ-Polyrizon rises as lab study shows improved nasal delivery for overdose drug** Shares of  drug developer Polyrizon PLRZ.O rise 5.2% to $14.25 premarket** Co says its experimental naloxone nasal spray delivered about 95% of the drug to the upper nasal cavity — a region that helps rapid absorption — vs ~80% for a commercial product** PLRZ's naloxone is used to quickly reverse opioid overdoses, per co** Co says less of the drug remained in the lower nasal area, which could reduce drainage and improve consistency** Study was conducted at the University of Parma; co says results support its broader intranasal drug delivery strategy** Shares down over 99% in 2025 (Reporting by Sahil Pandey in Bengaluru) ((Sahil.Pandey@thomsonreuters.com))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2614421330","isCrawlerRequest":true}